{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:38:05Z","timestamp":1771591085265,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007515","name":"Universidad de Valladolid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragility fractures (vertebral, humerus or hip) in a cohort of patients diagnosed with osteoporosis on active anti-osteoporotic therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For this retrospective longitudinal study, baseline and follow-up data on prescribed non-osteoporotic treatments and the occurrence of vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression models. The drugs evaluated with a possible beneficial effect were thiazides and statins, while the drugs evaluated with a possible harmful effect were antiandrogens, aromatase inhibitors, proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, GnRH agonists, thyroid hormones, and oral and inhaled corticosteroids.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Logistic regression analyses indicated that no treatment significantly improved fracture risk, with the only treatments that significantly worsened fracture risk being letrozole (OR\u2009=\u20090.18, <jats:italic>p<\/jats:italic>-value\u2009=\u20090.03) and oral corticosteroids at doses\u2009\u2264\u20095\u00a0mg\/day (OR\u2009=\u20090.16, <jats:italic>p<\/jats:italic>-value\u2009=\u20090.03) and\u2009&gt;\u20095\u00a0mg\/day (OR\u2009=\u20090.27, <jats:italic>p<\/jats:italic>-value\u2009=\u20090.04).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-023-03544-x","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T06:02:12Z","timestamp":1690610532000},"page":"1333-1339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry"],"prefix":"10.1007","volume":"79","author":[{"given":"Mar\u00eda Bego\u00f1a","family":"Coco-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Leal-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Bl\u00e1zquez-Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Arranz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Am\u00e9rigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Sosa-Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"D\u00edaz-Curiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ruiz-Mambrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Filgueira-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"P\u00e9rez-Castrill\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the OSTEOMED Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Filgueira-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Hern\u00e1ndez-de Sosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luz","family":"Calero-Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Armengol-Sucarrats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"de Escalante-Yanguas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Miranda-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Miranda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Giner-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Jare\u00f1o-Chaumel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Cotos-Canca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Rodero-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"S\u00e1nchez-Molini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado-Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Cobeta-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundo","family":"Tirado-Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"key":"3544_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795. https:\/\/doi.org\/10.1001\/jama.285.6.785","journal-title":"JAMA"},{"key":"3544_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4:368\u2013381. https:\/\/doi.org\/10.1007\/BF01622200","journal-title":"WHO Study Group Osteoporos Int"},{"key":"3544_CR3","doi-asserted-by":"publisher","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","DOI":"10.1007\/s11657-013-0136-1"},{"key":"3544_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.rceng.2021.12.008","volume":"222","author":"Riancho JA, Peris P, Gonz\u00e1lez-Mac\u00edas J, P\u00e9rez-Castrill\u00f3n JL; SEIOMM Osteoporosis Guidelines Writing Group","year":"2022","unstructured":"Riancho JA, Peris P, Gonz\u00e1lez-Mac\u00edas J, P\u00e9rez-Castrill\u00f3n JL; SEIOMM Osteoporosis Guidelines Writing Group (2022) Executive summary clinical practice guideline of postmenopausal, glucocortcioid-induced and male osteoporosis (2022 update). Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM). Rev Clin Esp (Barc) 222:432\u2013439. https:\/\/doi.org\/10.1016\/j.rceng.2021.12.008","journal-title":"Rev Clin Esp (Barc)"},{"key":"3544_CR5","doi-asserted-by":"publisher","unstructured":"Coco Mart\u00edn MB, Leal Vega L, Bl\u00e1zquez Cabrera JA, Navarro A et al; OSTEOMED Group (2022) Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry. Aging Clin Exp Res 34:1997\u20132004. https:\/\/doi.org\/10.1007\/s40520-022-02129-5","DOI":"10.1007\/s40520-022-02129-5"},{"key":"3544_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787. https:\/\/doi.org\/10.1007\/s001980200108","journal-title":"Osteoporos Int"},{"key":"3544_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/s0895-7061(03)00845-8","volume":"16","author":"JL P\u00e9rez-Castrill\u00f3n","year":"2003","unstructured":"P\u00e9rez-Castrill\u00f3n JL, Silva J, Justo I, Sanz A et al (2003) Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 16:453\u2013459. https:\/\/doi.org\/10.1016\/s0895-7061(03)00845-8","journal-title":"Am J Hypertens"},{"key":"3544_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1573402052952843","volume":"1","author":"JL Perez-Castrill\u00f3n","year":"2005","unstructured":"Perez-Castrill\u00f3n JL, Justo I, Sanz-Cantalapiedra A, Pueyo C et al (2005) Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture. Curr Hypertens Rev 1:61\u201366. https:\/\/doi.org\/10.2174\/1573402052952843","journal-title":"Curr Hypertens Rev"},{"key":"3544_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2174\/157341206776819337","volume":"2","author":"JL P\u00e9rez Castrill\u00f3n","year":"2006","unstructured":"P\u00e9rez Castrill\u00f3n JL, Abad L, Vega G, Sanz-Cantalapiedra A et al (2006) Effects of statins on bone markers, bone mineral density and fractures. Possible role in osteoporosis treatment. Curr Pharm Anal 2:161\u2013168. https:\/\/doi.org\/10.2174\/157341206776819337","journal-title":"Curr Pharm Anal"},{"key":"3544_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2174\/157339706778699878","volume":"2","author":"JL Perez-Castrill\u00f3n","year":"2006","unstructured":"Perez-Castrill\u00f3n JL, Sanz-Cantalapiedra A, Due\u00f1as A (2006) Beta-Blockers: effects on bone mineral density and fracture risk. Curr Rheumatol Rev 2:353\u2013357. https:\/\/doi.org\/10.2174\/157339706778699878","journal-title":"Curr Rheumatol Rev"},{"issue":"20","key":"3544_CR11","doi-asserted-by":"publisher","first-page":"30174","DOI":"10.1016\/j.rce.2020.06.004","volume":"S0014\u20132565","author":"JA Bl\u00e1zquez Cabrera","year":"2020","unstructured":"Bl\u00e1zquez Cabrera JA, Sosa Henriquez M, Diaz-Curiel M, S\u00e1nchez Molini P et al; in representation of OSTEOMED\u00a0(2020) Profile of patients who visit medical internists for an osteoporosis assessment: The OSTEOMED registry. Rev Clin Esp S0014\u20132565(20):30174. https:\/\/doi.org\/10.1016\/j.rce.2020.06.004","journal-title":"Rev Clin Esp"},{"key":"3544_CR12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.7326\/0003-4819-139-6-200309160-00010","volume":"139","author":"MW Schoofs","year":"2003","unstructured":"Schoofs MW, van der Klift M, Hofman A, de Laet CE et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:476\u2013482. https:\/\/doi.org\/10.7326\/0003-4819-139-6-200309160-00010","journal-title":"Ann Intern Med"},{"key":"3544_CR13","doi-asserted-by":"publisher","unstructured":"van der Burgh AC, Oliai Araghi S, Zillikens MC, Koromani F et al (2020) The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study. Bone 138:115475. https:\/\/doi.org\/10.1016\/j.bone.2020.115475","DOI":"10.1016\/j.bone.2020.115475"},{"key":"3544_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers MJ, Crockett JC, Coxon FP, M\u00f6nkk\u00f6nen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34\u201341. https:\/\/doi.org\/10.1016\/j.bone.2010.11.008","journal-title":"Bone"},{"key":"3544_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6:901\u2013910. https:\/\/doi.org\/10.1016\/S2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3544_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","volume":"79","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76\u201383. https:\/\/doi.org\/10.1007\/s00223-006-0021-7","journal-title":"Calcif Tissue Int"},{"key":"3544_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bone.2012.05.018","volume":"51","author":"R Rizzoli","year":"2012","unstructured":"Rizzoli R, Cooper C, Reginster JY, Abrahamsen B et al (2012) Antidepressant medications and osteoporosis. Bone 51:606\u2013613. https:\/\/doi.org\/10.1016\/j.bone.2012.05.018","journal-title":"Bone"},{"key":"3544_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00198-013-2446-y","volume":"25","author":"D Xing","year":"2014","unstructured":"Xing D, Ma XL, Ma JX, Wang J et al (2014) Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int 25:105\u2013120. https:\/\/doi.org\/10.1007\/s00198-013-2446-y","journal-title":"Osteoporos Int"},{"key":"3544_CR19","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00198-016-3605-8","volume":"27","author":"SM Park","year":"2016","unstructured":"Park SM, Ryu J, Lee DR, Shin D et al (2016) Zolpidem use and risk of fractures: a systematic review and meta-analysis. Osteoporos Int 27:2935\u20132944. https:\/\/doi.org\/10.1007\/s00198-016-3605-8","journal-title":"Osteoporos Int"},{"key":"3544_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.7326\/0003-4819-134-7-200104030-00009","volume":"134","author":"Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group","year":"2001","unstructured":"Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561\u2013568. https:\/\/doi.org\/10.7326\/0003-4819-134-7-200104030-00009","journal-title":"Ann Intern Med"},{"key":"3544_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40618-017-0753-4","volume":"41","author":"GR Williams","year":"2018","unstructured":"Williams GR, Bassett JHD (2018) Thyroid diseases and bone health. J Endocrinol Invest 41:99\u2013109. https:\/\/doi.org\/10.1007\/s40618-017-0753-4","journal-title":"J Endocrinol Invest"},{"key":"3544_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jbmr.3886","volume":"35","author":"M Pineda-Moncus\u00ed","year":"2020","unstructured":"Pineda-Moncus\u00ed M, Garcia-Giralt N, Diez-Perez A, Servitja S et al (2020) Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: Beneficial effect of bisphosphonates. J Bone Miner Res 35:291\u2013297. https:\/\/doi.org\/10.1002\/jbmr.3886","journal-title":"J Bone Miner Res"},{"key":"3544_CR23","doi-asserted-by":"publisher","unstructured":"de Sire A, Lippi L, Venetis K, Morganti S et al (2022) Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Front Oncol 11:829875. https:\/\/doi.org\/10.3389\/fonc.2021.829875","DOI":"10.3389\/fonc.2021.829875"},{"key":"3544_CR24","doi-asserted-by":"publisher","unstructured":"Liu ZM, Zhang M, Zong Y, Zhang D et al (2022) The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials. PLoS One 17:e0267706. https:\/\/doi.org\/10.1371\/journal.pone.0267706","DOI":"10.1371\/journal.pone.0267706"},{"key":"3544_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","volume":"13","author":"MA Amiche","year":"2018","unstructured":"Amiche MA, Abtahi S, Driessen JHM, Vestergaard P et al (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13:30. https:\/\/doi.org\/10.1007\/s11657-018-0424-x","journal-title":"Arch Osteoporos"},{"key":"3544_CR26","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00228-019-02743-9","volume":"75","author":"Q Dardonville","year":"2019","unstructured":"Dardonville Q, Salguiero E, Rousseau V, Chebane L et al (2019) Drug-induced osteoporosis\/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 75:1705\u20131711. https:\/\/doi.org\/10.1007\/s00228-019-02743-9","journal-title":"Eur J Clin Pharmacol"},{"key":"3544_CR27","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"3544_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445\u2013454. https:\/\/doi.org\/10.1016\/S2213-8587(18)30075-5","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03544-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T03:21:48Z","timestamp":1694748108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3544"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03544-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the Clinical Research Ethics Committee of the Albacete University Hospital Complex (Act 02\/11) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}